We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Graft Polymer (uk) Plc | LSE:GPL | London | Ordinary Share | GB00BMD1Z199 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 2.44% | 0.21 | 0.20 | 0.22 | 0.21 | 0.205 | 0.205 | 9,900,763 | 08:21:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 587k | -3.12M | -0.0014 | -1.50 | 4.71M |
15 July 2024
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Director resignation and launch of new corporate website and social media profiles
Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation of Mr. Pavel Kobzev from its board of directors with immediate effect. This follows the Company's recent divestiture of its industrial plastics business unit, Graft Polymer D.O.O., announced on 3 May 2024, and the successful completion of its recent fundraise, details of which were announced on 3 July 2024.
Additionally, the Company is pleased to announce the launch of its new corporate website and updated LinkedIn and X (formerly Twitter) profiles. These platforms are designed to reflect the Company's strategic focus on supporting biopharmaceutical companies to enhance the bioavailability, pharmacokinetics, and stability of their therapeutics.
Visit us online:
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director, Email: anthonytennyson@graftpolymer.co.uk
Yifat Steuer, CFO and Executive Director, Email: yifat@graftpolymer.co.uk
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner / James Reeve (Corporate Finance)
Guy McDougall (Sales)
+44 (0) 20 3328 5656
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc (LON:GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.
www.graftpolymer.co.uk | LinkedIn | X (formerly Twitter)
1 Year Graft Polymer (uk) Chart |
1 Month Graft Polymer (uk) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions